“…YAP’s transcriptional coactivation function is modulated by the HER4 intracellular domain (HER4-ICD) in vitro, but the clinical relevance of this has not been established. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Our results show that YAP is involved in trastuzumab resistance in HER2-positive breast carcinoma cells and that YAP and AKT may be developed as prognostic markers of neoadjuvant trastuzumab therapy in patients with HER2-positive breast cancer.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…SIMPLE SUMMARY: Monitoring of the pregnant mare and her fetus is based on hormone analysis and heart rate recordings which may differ among small, medium-size, and full-size horses. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…While the HER2-positive subtype lacks estrogen and progesterone receptors and overexpresses HER2, the TNBC subtype lacks estrogen, progesterone and HER2 receptors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: The significance of human epidermal growth factor receptor 2 (Her2) and nucleus-associated antigen Ki-67 expression remains controversial in gastric adenocarcinoma (GaC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The HER2-positive breast cancer subtype (HER2(+)-BC) displays a particularly aggressive behavior. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…She was still undergoing second-line anti-HER2 therapy and currently in a stable situation. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The prognosis of HER2-positive metastatic breast cancer (MBC) has radically changed in recent years and continues to improve due to the broad application of effective therapies like monoclonal antibodies and small molecules targeting HER2. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…PURPOSE: In 2007, the American Society of Clinical Oncology and the College of American Pathologists had established a human epidermal growth factor receptor 2 (HER2) testing guideline, which was updated in 2013 and subsequently in 2018. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…INTRODUCTION: The HER2 + tumor immune microenvironment is composed of macrophages, natural killer cells, and tumor infiltrating lymphocytes, which produce pro-inflammatory cytokines. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer. METHODS: Patients had advanced HER2-negative disease that progressed while receiving single-agent bevacizumab maintenance as a part of a previous chemotherapy plus bevacizumab regimen. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…IMPORTANCE: The neoadjuvant treatment options for ERBB2-positive (also known as HER2-positive) breast cancer are associated with different rates of pathologic complete response (pCR). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with endocrine therapy. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Prolonged hypersecretion of catecholamine induced by chronic stress may correlate with malignant progression of cancer. β2‐adrenergic receptor (β2‐AR) overexpressed in certain cancer cells may translate the signals from neuroendocrine system to malignant signals by interacting with oncoproteins, such as Her2. In the present study, we demonstrate that catecholamine stimulation activates the expression and proteolytic activity of ADAM10 by modulating the expression of miR‐199a‐5p and SIRT1 and also confirm that catecholamine induction triggers the activities of γ‐secretase, leading to shedding of Her2 extracellular domain (ECD) by ADAM10 and subsequent intramembranous cleavage of Her2 intracellular domain (ICD) by presenilin‐dependent γ‐secretase, nuclear translocation of Her2 ICD, and enhanced transcription of tumor metastasis‐associated gene COX‐2. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human epidermal growth factor receptor 2 (HER2) is the principal druggable target of GC, yet proper biomarkers for response/resistance prediction remain unveiled. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Few studies have explored HER2 status in cervical adenocarcinoma, particularly in the gastric‐type adenocarcinoma (GAC), a nonhuman‐papillomavirus‐related subtype with poor clinical outcomes. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Our aim was to evaluate the association of common polymorphisms in antioxidative genes with cardiotoxicity after adjuvant radiotherapy (RT) in HER2-positive breast cancer patients. METHODS: Our retrospective study included 101 HER2-positive early breast cancer patients who received trastuzumab and adjuvant RT. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a member of the ErbB family and is a key proto-oncogene in solid tumors. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso